Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Medtronic
Harvard Business School
Mallinckrodt

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SANCUSO

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Sancuso

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00450801 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma Completed University of Miami Phase 2 2004-04-01 RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.
NCT00868764 An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron Completed Prostrakan Pharmaceuticals Phase 1 2009-04-01 This study aims to evaluate the effect of age and BMI on the pharmacokinetics and safety of Sancuso®.
NCT00873197 PK, Tolerability and Safety of the co-Administration of Sancuso® (Transdermal Granisetron) and IV Granisetron Completed Prostrakan Pharmaceuticals Phase 1 2009-04-01 This study has been designed to investigate the pharmacokinetic and safety profile of the co-administration of intravenous (IV) and transdermal granisetron, as well as characterise the pharmacokinetics of multiple transdermal dosing.
NCT00890565 Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS) Completed Prostrakan Pharmaceuticals Phase 1 2009-05-01 This study aims to evaluate the electrocardiogram (ECG) effects of Sancuso® compared to placebo and moxifloxacin in healthy subjects.
NCT01275664 Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Suspended National Cancer Institute (NCI) N/A 2011-06-01 This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
NCT01275664 Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Suspended Gynecologic Oncology Group N/A 2011-06-01 This clinical trial is studying how well granisetron, aprepitant, and dexamethasone work in preventing nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer. Granisetron patch, aprepitant and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for stage II, stage III, or stage IV ovarian cancer.
NCT01536392 Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation Active, not recruiting Sancuso Phase 3 2012-03-01 The goal of this clinical research study is to compare granisetron (when given through a patch) to ondansetron (when taken by mouth) for reducing nausea and vomiting in women with cervical, endometrial, or vaginal cancer having chemoradiation. Granisetron and ondansetron are designed to help reduce nausea and vomiting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sancuso

Condition Name

Condition Name for Sancuso
Intervention Trials
Chemotherapy Induced Nausea and Vomiting 3
Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV) 2
Nausea 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sancuso
Intervention Trials
Vomiting 9
Nausea 6
Lymphoma, Mantle-Cell 1
Cystadenocarcinoma, Serous 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sancuso

Trials by Country

Trials by Country for Sancuso
Location Trials
United States 9
Korea, Republic of 2
United Kingdom 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sancuso
Location Trials
Pennsylvania 2
Washington 1
Texas 1
Rhode Island 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sancuso

Clinical Trial Phase

Clinical Trial Phase for Sancuso
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sancuso
Clinical Trial Phase Trials
Completed 5
Recruiting 3
Unknown status 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sancuso

Sponsor Name

Sponsor Name for Sancuso
Sponsor Trials
Prostrakan Pharmaceuticals 6
LG Life Sciences 2
National Cancer Institute (NCI) 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sancuso
Sponsor Trials
Other 8
Industry 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Dow
McKesson
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.